New drugs, decades in the making, are providing relief for migraines.

2018-12-11T12:47:38+00:0011/12/2018|Categories: New Treatment, News|Tags: , , |

Nancy Baum Lipsitz remembers the night the pain began. She’d had a glass of white wine with a friend and went to bed with a terrible headache. The next day, she still felt horrible, the beginning of what she called a “rolling tide” of near constant migraines and lower level headaches. For three years she dealt with the symptoms. Sometimes she got tunnel vision, or a visual aura, a warning that a big headache was on the way. Those felt like “someone taking a pick and jabbing it through my nose and eye,” she said. Then there was the vomiting, [...]

“Green light” to Lilly’s monoclonal antibody to migraine

2018-11-28T17:21:25+00:0028/11/2018|Categories: Industry, News|Tags: , , , , , , , |

Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes of migraine, blocks its function Administered with a month subcutaneous injection which can be applied to the patient with a pen or pre-filled syringe. In all three clinical trials, galcanezumab has shown significantly reducing the monthly average of migraine days and an improvement in functionality versus placebo. "Migraine is [...]

Lilly Receives Positive CHMP Opinion for Emgality

2018-10-17T12:24:24+00:0017/10/2018|Categories: Industry, News|Tags: , , , , |

INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month. TM In June 2018, Lilly announced the intended brand name, Emgality, was conditionally accepted by the U.S. Food and Drug Administration (FDA). Emgality is a humanized monoclonal antibody specifically designed to bind to the calcitonin gene-related peptide (CGRP), blocking its [...]

We and our partners use cookies, to collect browsing data to give you the best online experience and to personalize the content, play multimedia content, interact with social networks and perform browsing analytics. If you continue browsing we understand you accept the use of such technology. For more information visit our cookies policy Find out more

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close